Rhodiola Rosea for Altitude Sickness

Research suggests that Rhodiola rosea and its close relative Rhodiola crenulata may offer protective benefits at high altitude, with the most directly relevant evidence coming from a 2025 systematic review and meta-analysis of 19 randomized controlled trials showing that Rhodiola crenulata extract improved arterial oxygen saturation and blood oxygen levels comparably to conventional treatments and better than placebo, with a favorable safety profile. Supporting this, laboratory and animal studies indicate that salidroside, the primary active compound in Rhodiola, may help the body cope with low-oxygen conditions by stimulating red blood cell development, protecting red blood cells from oxidative damage, and shielding cardiac cells from hypoxic injury through multiple molecular pathways. A 2022 preclinical study further found that combining Rhodiola with acetazolamide, a standard altitude sickness drug, produced stronger effects on oxygen-sensing pathways than either treatment alone, while broader reviews of the plant's adaptogenic properties lend indirect support to its traditional use among high-altitude populations. The evidence base is promising but notable limitations apply, including that the clinical trials were conducted exclusively in China and primarily involved one species variant, preclinical findings do not always translate to humans, and the exact mechanisms behind Rhodiola's protective effects remain only partially understood.